Background: Despite methicillin-resistant Staphylococcus aureus (MRSA) being endemic in virtually all US health care facilities, there are no data on the prevalence of MRSA in US health care facilities.
Methods: We conducted a national prevalence survey of MRSA in inpatients at US health care facilities. The survey was developed, received institutional review board approval, and then distributed to all members of the Association for Professionals in Infection Control and Epidemiology, Inc. (APIC). Members were asked to complete the survey on one day during the period October 1 to November 16, 2006, reporting the number of inpatients with MRSA infection or colonization and facility-specific information.
Results: Personnel at 1237 hospitals completed the survey. Complete facility data were provided for 1187 (96%) of these health care facilities. All states were represented (mean, 23 facilities per state; range, 1-99). Respondents reported 8654 MRSA-colonized/infected patients in 187,058 inpatients; the overall MRSA prevalence rate was 46.3 per 1000 inpatients (34 infections and 12 colonizations per 1000 inpatients). Active MRSA surveillance testing was conducted by 29% of respondents: 54% used routine media, 38% used selective media, and 8% used polymerase chain reaction. Detailed data were provided on 7994 (92.4%) MRSA-colonized/infected patients. Our data suggest that approximately 70% of isolates were more consistent with health care-associated MRSA (HA-MRSA) than community-associated MRSA.
Conclusion: Our survey documents a much higher MRSA prevalence rate than previous studies using different methodologies. The majority of MRSA in inpatients appears to be HA-MRSA. Given that most facilities did not perform active surveillance testing, these are minimum estimates of the national burden of MRSA in US health care facilities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajic.2007.10.009 | DOI Listing |
Background: The autophagy lysosomal pathway (ALP) and the ubiquitin-proteasome system (UPS) are key proteostasis mechanisms in cells, which are dysfunctional in AD and linked to protein aggregation and neuronal death. Autophagy is over activated in Alzheimer's disease brain whereas UPS is severely impaired. Activating autophagy has received most attention, however recent evidence suggests that UPS can clear aggregate proteins and a potential therapeutic target for AD and protein misfolding diseases.
View Article and Find Full Text PDFBackground: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.
Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.
Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: Blood pressure (BP) management is an accessible therapeutic target for dementia prevention. BP variability (BPV) is a newer aspect of BP control recently associated with cognitive decline, dementia and Alzheimer's disease (AD), independent of traditionally targeted mean BP levels. Most of this work has relied on largely non-Hispanic White study samples in observational cohorts.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!